Aster Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Aster Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-163	Closed	-$3.8K	–	934
2025 Q4	$3.8K	Buy	+163	New	+$3.63K	﹤0.01%	902
2025 Q2	–	Sell	-3,801	Closed	-$87K	–	1132
2025 Q1	$87K	Buy	+3,801	New	+$85.6K	0.02%	691

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Aster Capital Management's CPRX Position: Q1 2026 in Review

Aster Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 163 shares — an estimated $3.8K sold.

Aster Capital Management first reported a position in CPRX in Q1 2025 and held it in 2 quarters. The position peaked at $87K in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Aster Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Aster Capital Management sold 163 Catalyst Pharmaceutical shares in Q1 2026, an estimated $3.8K.
Aster Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2025 and held it in 2 quarters.
Aster Capital Management's Catalyst Pharmaceutical position peaked at $87K in Q1 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.